文献速递肿瘤 PET/CT

18F-FDG PET/CT影像组学联合肌肉减少症评分预测食管胃癌患者无复发生存与总生存

Combined 18 F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer.
PubMed 文献 · Clin Nucl Med · 2022-05-11

本研究纳入145例接受根治性治疗的食管腺癌患者,利用治疗前18F-FDG PET/CT提取影像组学特征并测量L3水平骨骼肌指数评估肌肉减少症,结合临床病理参数构建预测模型。多因素分析显示,将肌肉减少症状态和影像组学特征加入临床模型可改善总生存和无复发生存的模型拟合。结论认为PET/CT影像组学联合临床病理参数和肌肉减少症测量可能改善非转移性食管胃腺癌患者的预后预测。

要点

  • 治疗前18F-FDG PET/CT影像组学联合肌肉减少症测量可改善食管胃腺癌预后模型拟合。
  • 肌肉减少症状态加入临床特征模型改善总生存模型拟合(似然比检验P=0.03)。
  • CT影像组学特征加入模型改善总生存(P=0.0037)和无复发生存(P=0.042)模型拟合。

核心结论

  • 基于PET/CT的影像组学联合临床病理参数和肌肉减少症测量可能改善非转移性食管胃腺癌患者的预后预测。

研究设计与样本

  • 纳入145例接受根治性治疗且具有治疗前18F-FDG PET/CT的食管腺癌患者。
  • 使用LIFEx软件评估PET和CT图像的纹理特征,通过CT图像上L3水平骨骼肌指数进行肌肉减少症测量。
  • 采用单因素和多因素分析构建包含影像组学参数、临床特征和骨骼肌指数评分的预后预测模型。

主要发现

  • 多因素分析将ECOG、手术T分期和N分期等临床病理参数与影像学肌肉减少症测量和影像组学特征结合,构建无复发生存和总生存的预测模型。
  • 将肌肉减少症状态加入仅含临床特征的模型改善总生存模型拟合(似然比检验P=0.03),加入CT特征亦改善总生存模型拟合(P=0.0037)。
  • 将肌肉减少症状态(P=0.051)、CT特征(P=0.042)和PET特征(P=0.011)加入模型改善无复发生存模型拟合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to determine if radiomic features combined with sarcopenia measurements on pretreatment 18 F-FDG PET/CT can improve outcome prediction in surgically treated adenocarcinoma esophagogastric cancer patients. PATIENTS AND METHODS: One hundred forty-five esophageal adenocarcinoma patients with curative therapeutic intent and available pretreatment 18 F-FDG PET/CT were included. Textural features from PET and CT images were evaluated using LIFEx software ( lifexsoft.org ). Sarcopenia measurements were done by measuring the Skeletal Muscle Index at L3 level on the CT component. Univariable and multivariable analyses were conducted to create a model including the radiomic parameters, clinical features, and Skeletal Muscle Index score to predict patients' outcome. RESULTS: In multivariable analysis, we combined clinicopathological parameters including ECOG, surgical T, and N staging along with imaging derived sarcopenia measurements and radiomic features to build a predictor model for relapse-free survival and overall survival. Overall, adding sarcopenic status to the model with clinical features only (likelihood ratio test P = 0.03) and CT feature ( P = 0.0037) improved the model fit for overall survival. Similarly, adding sarcopenic status ( P = 0.051), CT feature ( P = 0.042), and PET feature ( P = 0.011) improved the model fit for relapse-free survival. CONCLUSIONS: PET and CT radiomics derived from combined PET/CT integrated with clinicopathological parameters and sarcopenia measurement might improve outcome prediction in patients with nonmetastatic esophagogastric adenocarcinoma.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Anconina R, Ortega C, Metser U, et al. Combined 18 F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer. Clin Nucl Med. 2022. PMID: 35543637. doi:10.1097/RLU.0000000000004253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。